All In Biotech

Drug Trial Radar · NCT01641367

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

Last checked: Nov 20, 2026Latest source record: Mar 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 545 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

545

Actual

Start

Feb 22, 2013

Primary completion

Nov 23, 2016

Study completion Dec 31, 2018

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); AbbVie; Gilead Sciences; Janssen Pharmaceuticals; Merck Sharp & Dohme LLC; Dimagi Inc.
First posted
Jul 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was done to: * test a strategy of using a resistance test to choose anti-HIV drugs * see how well combinations of new anti-HIV drugs work to lower HIV infection * see if taking new anti-HIV drugs together is safe and tolerable * see if text messages improve people's anti-HIV drug-taking behavior (only at sites participating in the adherence study) * in people taking certain combinations of anti-HIV drugs with an anti-TB drug, compare how these drugs act in the body * to see how people do after they stop having frequent clinic visits as part of a research study

Conditions

  • HIV-1 Infection

Interventions

  • DarunavirDrug

    Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])

  • EtravirineDrug

    Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.

  • Emtricitabine/tenofovir disoproxil fumarateDrug

    Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.

  • RaltegravirDrug

    Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food

  • Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)Drug

    LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.

  • Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableDrug

    For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).

  • SOC adherence versus SOC+CPI adherenceOther

    * not participating in the adherence randomization; OR * randomized to SOC adherence; OR * randomized to SOC+CPI adherence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 WeeksTime frame: 48 weeks after the date of entry

Locations

19 sites in 10 countries. Site status is shown where the registry gives one.

  • Instituto de Pesquisa Clinica Evandro Chagas (12101)

    Rio de Janeiro, Brazil

  • Hospital Nossa Senhora da Conceicao CRS (12201)

    Porto Alegre, Rio Grande do Sul, Brazil

  • GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS

    Port-au-Prince, Haiti

  • Les Centres GHESKIO CRS (30022)

    Port-au-Prince, Bicentaire, Haiti

  • BJ Medical College CRS (31441)

    Pune, Maharashtra, India

  • Chennai Antiviral Research and Treatment (CART) CRS (11701)

    Chennai, Taramani, India

  • AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)

    Eldoret, Kenya

  • Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460)

    Kisumu, Kenya

  • Malawi CRS (12001)

    Lilongwe, Malawi

  • Barranco CRS (11301)

    Lima, Peru

  • San Miguel CRS (11302)

    San Miguel, Lima region, Peru

  • Durban Adult HIV CRS (11201)

    Durban, South Africa

  • Soweto ACTG CRS (12301)

    Johannesburg, South Africa

  • University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)

    Johannesburg, Gauteng, South Africa

  • Family Clinical Research Unit (FAM-CUR) CRS (8950)

    Cape Town, West Cape, South Africa

  • 31784 Chiang Mai University HIV Treatment CRS

    Chiang Mai, Thailand

  • 31802 Thai Red Cross AIDS Research Centre (TRC-ARC) CRS

    Bangkok, Patumwan, Thailand

  • JCRC CRS

    Kampala, Uganda

  • UZ-Parirenyatwa CRS (30313)

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.